EX-1
from SC 13D/A
1 page
Exhibit 1 Joint Filing Agreement Pursuant to Rule 13d-1(k)(1) the Undersigned Acknowledge and Agree That the Foregoing Statement on Schedule 13d Is Filed on Behalf of Each of the Undersigned and That All Subsequent Amendments to This Statement on Schedule 13d Shall Be Filed on Behalf of Each of the Undersigned Without the Necessity of Filing Additional Joint Filing Agreements. the Undersigned Acknowledge That Each Shall Be Responsible for the Timely Filing of Such Amendments, and for the Completeness and Accuracy of the Information Concerning It Contained Therein, but Shall Not Be Responsible for the Completeness and Accuracy of the Information Concerning the Others, Except to the Extent That It Knows or Has Reason to Believe That Such Information Is Inaccurate. This Agreement May Be Executed in Any Number of Counterparts and All of Such Counterparts Taken Together Shall Constitute One and the Same Instrument. Dated: October 12, 2005 Third Point LLC By: /S/ Daniel S. Loeb Name: Daniel S. Loeb Title: Chief Executive Officer Third Point Offshore Fund, Ltd. By: /S/ Daniel S. Loeb Name: Daniel S. Loeb Title: Director /S/ Daniel S. Loeb Daniel S. Loeb [Joint Filing Agreement for Schedule 13d With Respect to Ligand Pharmaceuticals Incorporated]
12/34/56
EX-1
from SC 13G/A
1 page
Exhibit 1 Joint Filing Agreement This Will Confirm the Agreement by and Among the Undersigned That the Schedule 13g/a Filed With the Securities and Exchange Commission on or About the Date Hereof With Respect to the Beneficial Ownership by the Undersigned of the Common Stock of Ligand Pharmaceuticals Incorporated Is Being Filed, and All Amendments Thereto Will Be Filed, on Behalf of Each of the Persons and Entities Named Below in Accordance With Rule 13d-1(k) Under the Securities Exchange Act of 1934, as Amended. This Agreement May Be Executed in Two or More Counterparts, Each of Which Shall Be Deemed an Original, but All of Which Together Shall Constitute One and the Same Instrument. This Joint Filing Agreement Shall Be Filed as an Exhibit to Such Statement. Dated: February 14, 2005 Highbridge International LLC By: /S/ Howard Feitelberg Howard Feitelberg, Director Highbridge Capital Corporation By: /S/ Howard Feitelberg Howard Feitelberg, Controller Highbridge Capital Management, LLC By: /S/ Ronald S. Resnick Ronald S. Resnick, Managing Partner /S/ Glenn Dubin - Glenn Dubin /S/ Henry Swieca - Henry Swieca
12/34/56
EX-1
from SC 13G
1 page
Exhibit 1 Joint Filing Agreement in Accordance With Rule 13d-1(k) (1) (III) Under the Securities Exchange Act of 1934, as Amended, the Persons Named Below Agree to the Joint Filing on Behalf of Each of Them of a Statement on Schedule 13g Filed on February 13, 2004 (Including Amendments Thereto) With Respect to the Common Stock of Ligand Pharmaceuticals Incorporated. This Joint Filing Agreement Shall Be Filed as an Exhibit to Such Statement. Dated: February 13, 2004 Highbridge International LLC By: /S/ Howard Feitelberg Howard Feitelberg, Director Highbridge Capital Corporation By: /S/ Howard Feitelberg Howard Feitelberg, Controller Highbridge Capital Management, LLC By: /S/ Ronald S. Resnick Ronald S. Resnick, Managing Director
12/34/56
EX-1.1
from SC 13G
1 page
Ex-1.1 Otherdoc 2 0002.txt Joint Filing Agreement Exhibit 1.1 Joint Filing Agreement the Undersigned Hereby Agree That the Statement on This Schedule 13g, Dated November 29, 2002, (The "Schedule 13g"), With Respect to the Common Stock, Par Value $0.001 Per Share, of Ligand Pharmaceuticals Incorporated Is Filed on Behalf of Each of US Pursuant to and in Accordance With the Provisions of Rule 13d-1(k) Under the Securities and Exchange Act of 1934, as Amended, and That This Agreement Shall Be Included as an Exhibit to This Schedule 13g. Each of the Undersigned Agrees to Be Responsible for the Timely Filing of the Schedule 13g, and for the Completeness and Accuracy of the Information Concerning Itself Contained Therein. This Agreement May Be Executed in Any Number of Counterparts, All of Which Taken Together Shall Constitute One and the Same Instrument. in Witness Whereof, the Undersigned Have Executed This Agreement as of the 29th Day of November, 2002. Orbimed Advisors Inc. By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: President Orbimed Advisors LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member
12/34/56
EX-1.1
from SC 13G
1 page
Ex-1.1 Otherdoc 2 0002.txt Joint Filing Agreement Exhibit 1.1 Joint Filing Agreement the Undersigned Hereby Agree That the Statement on This Schedule 13g, Dated November 29, 2002, (The "Schedule 13g"), With Respect to the Common Stock, Par Value $0.001 Per Share, of Ligand Pharmaceuticals Incorporated Is Filed on Behalf of Each of US Pursuant to and in Accordance With the Provisions of Rule 13d-1(k) Under the Securities and Exchange Act of 1934, as Amended, and That This Agreement Shall Be Included as an Exhibit to This Schedule 13g. Each of the Undersigned Agrees to Be Responsible for the Timely Filing of the Schedule 13g, and for the Completeness and Accuracy of the Information Concerning Itself Contained Therein. This Agreement May Be Executed in Any Number of Counterparts, All of Which Taken Together Shall Constitute One and the Same Instrument. in Witness Whereof, the Undersigned Have Executed This Agreement as of the 29th Day of November, 2002. Orbimed Advisors Inc. By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: President Orbimed Advisors LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member
12/34/56
EX-1.1
from SC 13G
1 page
Ex-1.1 Otherdoc 2 0002.txt Joint Filing Agreement Exhibit 1.1 Joint Filing Agreement the Undersigned Hereby Agree That the Statement on This Schedule 13g, Dated November 29, 2002, (The "Schedule 13g"), With Respect to the Common Stock, Par Value $0.001 Per Share, of Ligand Pharmaceuticals Incorporated Is Filed on Behalf of Each of US Pursuant to and in Accordance With the Provisions of Rule 13d-1(k) Under the Securities and Exchange Act of 1934, as Amended, and That This Agreement Shall Be Included as an Exhibit to This Schedule 13g. Each of the Undersigned Agrees to Be Responsible for the Timely Filing of the Schedule 13g, and for the Completeness and Accuracy of the Information Concerning Itself Contained Therein. This Agreement May Be Executed in Any Number of Counterparts, All of Which Taken Together Shall Constitute One and the Same Instrument. in Witness Whereof, the Undersigned Have Executed This Agreement as of the 29th Day of November, 2002. Orbimed Advisors Inc. By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: President Orbimed Advisors LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member
12/34/56
